Post-approval Uses of Clinical Data, Phase IV Data, and Sales and Marketing Data Visualizations

  • Sam Weerahandi
  • Birol Emir
  • Ed Whalen


This chapter discusses some useful graphics in Phase IV and Sales and Marketing applications. In the first half of the chapter we show some useful presentations of existing clinical trial data and post-approval Phase IV studies’ data. Then, we undertake some applications in Sales and Marketing ranging from various trend analyses to in-depth analysis of field force optimization; in each section, a brief introduction to the application followed by some simple graphics highlighting findings in an easy to interpret manner are presented.

Most illustrations in this chapter are based on simulated data rather than actual data, and yet they are representative of real world situations.


Control Chart Field Representative Mixed Model Repeated Measure High Placebo Response Trend Break 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Amaratunga D, Cabrera J (2001) Analysis of data from viral DNA microchips. Journal of the American Statistical Association 96:1161–1170CrossRefGoogle Scholar
  2. Bouhassira D, Attal N, Fermanian J et al (2004) Development and validation of the neuropathic pain symptom inventory. Pain 108:248–257PubMedCrossRefGoogle Scholar
  3. Cabrera J, Emir B (2012) Fisher-Yates normalization for questionnaire data. Technical report (2012). Department of Statistic sand Biostatistics, Rutgers UniversityGoogle Scholar
  4. Chow GC (1960) Tests of equality between subsets of coefficients in two linear regressions. Econometrica 28:591–605CrossRefGoogle Scholar
  5. Freeman R, Emir B, Murphy TK, Xu, Y, Whalen E (2010) Placebo response characteristics in eight pregabalin diabetic peripheral neuropathy trials. Presented at third international congress on neuropathic pain, 27–30 May, Athens, GreeceGoogle Scholar
  6. French, J, Cabrera J, Emir B, Whalen E (2011) Designing a new proof-of-principle (PoP) trial for treatment of partial seizures to demonstrate efficacy with minimal sample size and duration—a case study. Pfizer Internal Report (2011). PCBU Statistics, New York, NYGoogle Scholar
  7. ICH Topic E 8, General Considerations for Clinical Trials (1998)
  8. Page ES (1954) Continuous Inspection Scheme. Biometrika 41 (1/2): 100–115Google Scholar
  9. Weerahandi S (1987) Testing regression equality with unequal variances. Econometrica 55:1211–1215CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, New York 2012

Authors and Affiliations

  1. 1.Pfizer Inc.New YorkUSA

Personalised recommendations